Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib

被引：10

作者：

Angona, Anna ^{[1
,2
,3
]}

Alvarez-Larran, Alberto ^{[1
,2
,3
]}

Bellosillo, Beatriz ^{[3
,4
,5
]}

Longaron, Raquel ^{[3
,4
]}

Fernandez-Rodriguez, Concepcion ^{[2
,3
]}

Besses, Carlos ^{[1
,3
]}

机构：

[1] Hosp Mar, Dept Haematol, Barcelona, Spain

[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain

[3] Hosp Mar, Med Res Inst, Grp Rec Clin Aplicada Neoplasies Hematol IMIM, Barcelona, Spain

[4] Hosp Mar, Dept Pathol, Barcelona, Spain

[5] Univ Pompeu Fabra, Barcelona, Spain

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 172卷 / 04期

关键词：

myeloproliferative disorders; progenitor cells; JAK2; V617F; additional mutations; ruxolitinib; MUTATIONS;

D O I：

10.1111/bjh.13535

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：639 / 642

页数：4

共 10 条

[1] Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera [J].

Angona, Anna ;

Alvarez-Larran, Alberto ;

Bellosillo, Beatriz ;

Martinez-Aviles, Luz ;

Camacho, Laura ;

Fernandez-Rodriguez, Concepcion ;

Pairet, Silvia ;

Longaron, Raquel ;

Ancochea, Agueda ;

Senin, Alicia ;

Florensa, Lourdes ;

Besses, Carles .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) :251-257

[2] Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms [J].

Brecqueville, Mandy ;

Rey, Jerome ;

Bertucci, Francois ;

Coppin, Emilie ;

Finetti, Pascal ;

Carbuccia, Nadine ;

Cervera, Nathalie ;

Gelsi-Boyer, Veronique ;

Arnoulet, Christine ;

Gisserot, Olivier ;

Verrot, Denis ;

Slama, Borhane ;

Vey, Norbert ;

Mozziconacci, Marie-Joelle ;

Birnbaum, Daniel ;

Murati, Anne .

GENES CHROMOSOMES & CANCER, 2012, 51 (08) :743-755

[3] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[4] Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood [J].

Majeti, Ravindra ;

Park, Christopher Y. ;

Weissman, Irving L. .

CELL STEM CELL, 2007, 1 (06) :635-645

[5] Effect of Mutation Order on Myeloproliferative Neoplasms [J].

Ortmann, Christina A. ;

Kent, David G. ;

Nangalia, Jyoti ;

Silber, Yvonne ;

Wedge, David C. ;

Grinfeld, Jacob ;

Baxter, E. Joanna ;

Massie, Charles E. ;

Papaemmanuil, Elli ;

Menon, Suraj ;

Godfrey, Anna L. ;

Dimitropoulou, Danai ;

Guglielmelli, Paola ;

Bellosillo, Beatriz ;

Besses, Carles ;

Dohner, Konstanze ;

Harrison, Claire N. ;

Vassiliou, George S. ;

Vannucchi, Alessandro ;

Campbell, Peter J. ;

Green, Anthony R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (07) :601-612

[6] Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera [J].

Swierczek, Sabina I. ;

Yoon, Donghoon ;

Bellanne-Chantelot, Christine ;

Kim, Soo Jin ;

Saint-Martin, Cecile ;

Delhommeau, Francois ;

Najman, Albert ;

Prchal, Josef T. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (05) :775-778

[7]

Vannucchi A., 2015, NEW ENGL J MED, V372, P435

[8] A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea [J].

Verstovsek, Srdan ;

Passamonti, Francesco ;

Rambaldi, Alessandro ;

Barosi, Giovanni ;

Rosen, Peter J. ;

Rumi, Elisa ;

Gattoni, Elisabetta ;

Pieri, Lisa ;

Guglielmelli, Paola ;

Elena, Chiara ;

He, Shui ;

Contel, Nancy ;

Mookerjee, Bijoyesh ;

Sandor, Victor ;

Cazzola, Mario ;

Kantarjian, Hagop M. ;

Barbui, Tiziano ;

Vannucchi, Alessandro M. .

CANCER, 2014, 120 (04) :513-520

[9] A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis [J].

Verstovsek, Srdan ;

Mesa, Ruben A. ;

Gotlib, Jason ;

Levy, Richard S. ;

Gupta, Vikas ;

DiPersio, John F. ;

Catalano, John V. ;

Deininger, Michael ;

Miller, Carole ;

Silver, Richard T. ;

Talpaz, Moshe ;

Winton, Elliott F. ;

Harvey, Jimmie H., Jr. ;

Arcasoy, Murat O. ;

Hexner, Elizabeth ;

Lyons, Roger M. ;

Paquette, Ronald ;

Raza, Azra ;

Vaddi, Kris ;

Erickson-Viitanen, Susan ;

Koumenis, Iphigenia L. ;

Sun, William ;

Sandor, Victor ;

Kantarjian, Hagop M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :799-807

[10] JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis [J].

Wang, Xiaoli ;

Ye, Fei ;

Tripodi, Joseph ;

Hu, Cing Siang ;

Qiu, Jiajing ;

Najfeld, Vesna ;

Novak, Jesse ;

Li, Yan ;

Rampal, Raajit ;

Hoffman, Ronald .

BLOOD, 2014, 124 (19) :2987-2995

← 1 →